Galectin Therapeutics Inc. (GALT)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Galectin Therapeutics Inc. (“Galectin” or “the Company”) (NASDAQ: GALT). Investors who purchased Galectin securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Galectin has violated federal securities laws.
Galectin Investigation Details
On December 19, 2025, Galectin announced that “the U.S. Food and Drug Administration (FDA) has provided a written response, and subsequent communications, to the Company’s previously submitted Type C meeting request regarding the development program for belapectin, its investigational galectin-3 inhibitor. The FDA converted the Company’s initial request for an in-person or teleconference meeting to a written response.” The Company added that it would pursue a follow-up Type C meeting to resolve key aspects of its trial design. Following this news, Galectin’s shares fell 28.9% on the same day.
What’s Next for Galectin Investors?
If you are aware of any facts relating to this investigation or purchased Galectin securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
No Cost to Galectin Investors
We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC For Galectin Securities Investigation?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace,” said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]
Attorney advertising.
Prior results do not guarantee similar outcomes.